Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000166501 | SCV000217300 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-07-22 | criteria provided, single submitter | clinical testing | The p.G866D variant (also known as c.2597G>A), located in coding exon 7 of the PALB2 gene, results from a G to A substitution at nucleotide position 2597. The glycine at codon 866 is replaced by aspartic acid, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000635797 | SCV000757220 | uncertain significance | Familial cancer of breast | 2023-08-07 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PALB2 protein function. ClinVar contains an entry for this variant (Variation ID: 186848). This variant has not been reported in the literature in individuals affected with PALB2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 866 of the PALB2 protein (p.Gly866Asp). |
Color Diagnostics, |
RCV000166501 | SCV001339504 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-11-20 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000635797 | SCV004202646 | uncertain significance | Familial cancer of breast | 2023-05-05 | criteria provided, single submitter | clinical testing |